Vizsgálati helyszín
Mammazentrum Hamburg MVZ GbR
Hamburg, 20357, NémetországMég nincs intézményhez kötve
- 17futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis3 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Toboroz11 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Lezárult2 vizsgálat
- Fő szponzor
- AstraZeneca3 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- AGO Research GmbH1 vizsgálat
- AGO Study Group1 vizsgálat
- AstraZeneca AB1 vizsgálat
- és még 11
Futó vizsgálatok
Toboroz
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· 3. fázis· BeOne Medicines I GmbH· Forrás
Toboroz
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
2024-511392-15-00· 3. fázis· WSG Women's Cancer Study Group GmbH· Forrás
Toboroz
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Toboroz
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244· 3. fázis· Women's Cancer Study Group GmbH· Forrás
Toboroz
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127· 2. fázis· MedSIR· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
NCT05452213· 4. fázis· Institut Für Frauengesundheit GmbH· Forrás
Toboroz
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082· 3. fázis· AGO Study Group· Forrás
Toboroz
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
NCT04644289· 2. fázis· AGO Research GmbH· Forrás
Fut, nem toboroz
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer
NCT04784714· 3. fázis· AstraZeneca AB· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek